SAQUINAVIR

这是一项关于药物安全性和活性的多中心开放标签研究 沙奎那韦软胶囊制剂与其他制剂的联合应用 抗逆转录病毒药物。沙奎那韦是一种新的抗病毒药物，正在 研究人类免疫缺陷病毒(HIV)的治疗。 沙奎那韦的作用方式与另一组抗艾滋病毒药物不同 称为逆转录酶抑制剂的药物(例如，AZT、ddC、ddi 和d4T)。这种药物仍在研发中。这种药给了三个人 每天一次，但必须在吃完后立即服用 对身体有良好的吸收作用。该协议旨在 建立沙奎那韦在高于以下剂量暴露时的安全性 与目前市场上销售的硬明胶配方和 提供沙奎那韦与抗肿瘤药物联合应用的安全性和活性数据。 逆转录病毒药物。

This is a multi-center open label study of the safety and activity of Saquinavir soft gelatin capsule formulation in combination with other antiretroviral drugs. Saquinavir is a new antiviral drug that is being studied for the treatment of human immunodeficiency virus (HIV). Saquinavir works in a different way from another group of anti-HIV medication called reverse transcriptase inhibitors (e.g., AZT, ddC, ddI and D4T). The drug is still in development. The drug is given three times a day by mouth but must be taken immediately after eating for it to have good absorption into the body. This protocol is designed to establish the safety profile of Saquinavir at higher exposures than those possible with the currently marketed hard gelatin formulation and to provide safety and activity data on combining saquinavir with anti- retroviral drugs.